Healthcare

The company is approaching a potentially decisive period, with a US FDA 510(k) submission for its autism diagnostic targeted around year-end 2026. For a pre-commercial medical technology company, regulatory submissions of this kind represent genuine inflection points, and the period leading up to them …

The tension in the Clinuvel story is a familiar one for profitable but slow-growing companies. FY2026 showed modest declines inRevenueand profit, driven partly by a non-cash currency effect, even as cash reserves grew and the company pushed ahead with its US expansion. For long-term …

Rapid, consistentRevenuegrowth has made Biome one of the ASX healthcare small-caps investors are watching closely.

• Underlying EBITMarginof approximately 74.9% — among the highest in the ASX healthcare sector.

Australia's largest private health insurer rarely produces fireworks, and its FY2026 result was true to type: modest profit growth, a bigger dividend and steady customer gains, delivered against intensifying competition. Yet the market marked Medibank Private lower on results day, a reminder that for …

• Adjusted EBITDA jumped 146% to US$52 million from US$21 million; grossMarginexpanded to 55% from 53%.

• Recent company updates provide the main operational or financial evidence.